FDA advisors say no to MDMA. What’s the impact? With Josh Hardman
Business Trip
Intro
This chapter explores the critical FDA decision regarding MDMA-assisted therapy for PTSD and its implications for patients and the psychedelic industry. It highlights the advisory committee meeting where experts assessed the drug application from Lycos Therapeutics and discusses the influence of these committees on drug development in mental health.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
